Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

19:36 EDT 8th October 2015 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 16,000+

Extremely Relevant

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer

New Agent Active in Refractory Metastatic Colorectal Cancer

Treatment with TAS-102 improved survival in heavily pretreated patients with metastatic colorectal cancer, including those refractory to fluorouracil. Medscape Medical News

FDA approves ramucirumab for metastatic colorectal cancer

The US Food and Drug Administration has approved ramucirumab (Cyramza) for use in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed on a first line bevacizumab-, oxaliplatin- ...

Lilly's Cryamza Receives Fourth FDA Approval

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration (FDA) approval for Cryamza (ramucirumab). Cryamza (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with Folfiri (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior ther...

Global Colorectal Cancer Drugs Market 2015-2019

About Colorectal Cancer Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in th...

Add panitumumab or bevacizumab to improve first-line metastatic colorectal cancer therapy?

Dr Rivera talks to ecancertv at ECC 2015 about the final analysis of the PEAK randomized phase II study in patients with metastatic colorectal cancer and ways of improving upon current therapy. The primary endpoint was progression-free survival, wh...

Lonsurf® Approved for the Treatment of Colorectal Cancer

The United States Food and Drug Administration (FDA) has approved the oral agent, Lonsurf® (trifluridine and tipiracil), for the treatment of colorectal cancer. Colorectal cancer remains the second leading cause of cancer-related deaths in the U.S. ...


Colorectal cancer: An intravenous probe for colorectal cancer screening

Early detection of colorectal lesions is the cornerstone of cancer prevention. Intravenous administration of a novel fluorescent peptide probe now enables the screening of the whole colorectal area using near-infrared fluorescence colonoscopy, an app...

How aspirin fights colorectal cancer

Taking aspirin reduces a person's risk of colorectal cancer, but the molecular mechanisms involved have remained unknown until a recent discovery. discovered that aspirin might exert its chemopreventive activity against colorectal cancer, at least pa...

New approach holds promise for earlier, easier detection of colorectal cancer

(California Institute of Technology) Chemists at Caltech have developed a new sensitive electrochemical technique capable of detecting colorectal cancer in tissue samples -- a method that could one day be used in clinical settings for the early diagn...

Effects of aspirin on colorectal cancer

In this interview Dr Din, a Cancer Research UK Clinician Scientist and Honorary Consultant Colorectal Surgeon, discusses her work looking at the use of aspirin as a chemopreventative agent in colorectal cancer (CRC) at the 2015 Scientific Conference ...

Colorectal cancer: Back to the stroma—the real villain in colorectal cancer?

The cells responsible for particular gene signatures in large-scale microarray studies of colorectal cancer have now been revealed. In doing so, the gene signature associated with poor prognosis is shown to be predominantly of stromal origin.

Advances in the care of patients with mucinous colorectal cancer

Mucinous colorectal cancer has, in the past, been associated with inferior responses to treatment, and worse patient outcomes compared with other colorectal cancer subtypes; although, this situation has improved in the past 10–15 years. In this Rev...

Researchers examine risk factors/patient outcomes associated with colorectal cancer

About 20 percent of colorectal cancer patients have cancers that have spread beyond the colon at the time of their diagnosis. In a new study, researchers provide a detailed comparison of patient outcomes associated with synchronous and sequential col...

Adding Bevacizumab to Chemotherapy Improves PFS in Endometrial Cancer

The addition of bevacizumab to carboplatin/paclitaxel chemotherapy increases progression-free survival in advanced/recurrent endometrial cancer patients.

AAPS PharmSciTech: Topical Delivery of 5-Fluorouracil from Pheroid™ Formulations and the In Vitro Efficacy Against Human Melanoma

Type: Original PaperDrug delivery vehicles can influence the topical delivery and the efficacy of an active pharmaceutical ingredient (API). In this study, the influence of Pheroid™ technology, which is a unique colloidal drug delivery system, on t...

Biothera Immunotherapy Combination Results in Tumor Reduction During Maintenance Phase of Non-Small Cell Lung Cancer Study

The combination of the investigational cancer immunotherapy Imprime PGG and the monoclonal antibody bevacizumab achieved additional meaningful reductions in tumor burden during the maintenance phase of Biothera’s recent phase 2 clinical trial in non-small cell lung cancer (NSCLC). The new data will be released today at the European Lung Cancer Conference. ...

Patients with lowest BMI have shortest survival in pooled analysis of bev in mCRC

(European Society for Medical Oncology) Patients with the lowest body mass index had the shortest overall survival in an analysis of bevacizumab studies in metastatic colorectal cancer presented for the first time at the ESMO 17th World Congress on G...

Researcher calls for changes to colorectal cancer screening guidelines

(University of Pennsylvania School of Medicine) Colorectal cancer will claim the lives of close to 50,000 Americans this year, according to the American Cancer Society. Screening is the most effective way to reduce the risk of dying from the disease,...

ECC 2015: Discovery of differences between tumours of younger and older colorectal cancer patients may lead to better treatments

Colorectal cancer (CRC) is on the rise among younger patients. Although some of the younger-onset cases can be explained by hereditary factors, the majority arise spontaneously. Researchers have now found that tumours in younger colorectal cancer.....

Mouse models of human colorectal cancer generated through chemokine targeting

by ecancer reporter Clare Sansom Xenografts of human colorectal cancer (CRC) cells into mouse models have yielded many important insights into the pathogenesis of this disease and its treatment. However, none of the mouse models of colorectal canc...

Neoadjuvant Bevacizumab Shows Promise in HER2-Negative Breast Cancer

A phase III trial demonstrated efficacy and safety of adding bevacizumab (Avastin) to standard neoadjuvant chemotherapy in patients with HER2-negative breast cancer.

Fluorouracil Cream May Squelch Actinic Keratoses (CME/CE)

(MedPage Today) -- Fluorouracil beats out control cream in long-term randomized trial.

Researchers discover component of cinnamon prevents colorectal cancer in mice

Research conducted at the University of Arizona College of Pharmacy and the UA Cancer Center indicates that a compound derived from cinnamon is a potent inhibitor of colorectal cancer.

Teva Recalls Six More Lots of Fluorouracil Injection

The recall of Adrucil is due to the potential presence of particulate matter identified as an aggregate of silicone rubber pieces from a filler diaphragm and fluorouracil crystals. News Alerts


News Quicklinks